Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066698 · ClinicalTrials.gov registry record · Phase 2
ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
A Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05066698: Clinical Trial Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
NCT05066698 is a Phase 2 study that was terminated before completion, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05066698, a Phase 2 study, was terminated before completion, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.
Primary Outcome
Proportion of subjects with clinical success between ST266 and placebo arms, defined as complete re-epithelialization of the corneal epithelial defect by week 8 of treatment.
Interventions
- BIOLOGICAL ST266
- OTHER 0.67% Sodium Chloride Ophthalmic Solution
- BIOLOGICAL Open-label ST266
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 2 |
Why NCT05066698 stopped before completion
NCT05066698 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which ST266 is the first listed.
NCT05066698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05066698 about?
NCT05066698 is a clinical study titled "ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects". The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months po...
What is the current status of trial NCT05066698?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-04-27. Estimated completion is 2022-09-07.
What interventions are being tested in trial NCT05066698?
The interventions under investigation include: ST266 (BIOLOGICAL), 0.67% Sodium Chloride Ophthalmic Solution (OTHER), Open-label ST266 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05066698?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05066698's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI